Health authorities in England are launching a vaccination campaign against meningitis B, with approximately one million young people eligible to receive the free jab. The initiative follows an outbreak in Kent in March that resulted in 29 confirmed or suspected cases and two deaths, described as unprecedented in scale. Nearly 90,000 doses have already been administered, with an additional 135,000 appointments scheduled for the coming weeks.
The vaccine is being offered to 17 and 18-year-olds in sixth form and to students under age 25 entering residential university or further education settings for the first time in autumn. Eligible individuals include those born between specific date ranges as well as international students studying in England. The vaccination requires two doses administered at least 28 days apart to provide optimal protection. Walk-in services are available at participating pharmacies across England, and those already registered with a GP can book through the NHS National Booking Service.
According to NHS England, first-year university students face a risk of meningitis infection approximately seven times higher than their peers not attending university, primarily due to increased social mixing and shared accommodation. Meningitis B infection can cause severe complications including inflammation of the brain lining and sepsis, potentially resulting in life-threatening outcomes or permanent disabilities such as hearing loss and amputations. The vaccine contains no live bacteria and cannot cause meningitis, though common side effects include mild injection site reactions and temporary fever or headache.
The MenB vaccine was incorporated into the NHS childhood immunization program for babies born after 1 July 2015, leaving older teenagers and young adults unprotected. Research suggests the vaccine may not prevent person-to-person transmission, does not cover all B strain variants, and does not provide indefinite protection. UK vaccine experts are recommending that government officials consider implementing routine MenB vaccination for all teenagers at approximately age 15, though individual nations will make their own decisions. Officials emphasize that eligible individuals should come forward for vaccination despite these limitations, as the vaccine can prevent serious illness among high-risk populations.
Around 10,000 people in the Kent region had already received the vaccine as part of the immediate outbreak response. Each UK nation has developed its own implementation plans, though all are offering the vaccine to students completing their final year of secondary education in summer 2026, as well as young adults aged 18-25 entering higher education settings for the first time in autumn 2026.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI